Although some work on rare diseases is clearly clinical investigation and some clearly research, much activity falls uneasily between the two. Where should we draw the line and how can we ensure research gets appropriate ethical review?
Consider this case. A clinical geneticist telephoned a medically qualified researcher to discuss a patient with an unusual combination of clinical features. The patient presented a puzzle for diagnosis and for counselling about the genetic risk. Two months later, the clinician sent the researcher DNA from the patient, together with clinical photographs and copies of clinical letters. No mutation hotspots were found in relevant genes, and the sample was added to a "research panel." The clinician made further contact two years later, asking whether there were any positive results (the reply was negative) and providing some further clinical information.
Eventually, a further year and a half later and after tests of 13 genes had given negative results, the researcher contacted the clinician to say that a potentially pathogenic change in the DNA had been identified. The clinician was asked to obtain samples from the unaffected parents. The mutation was not present in either parent, establishing that the change had arisen de novo in the patient and was the cause of the clinical problem. Hence, three and a half years after the initial contact, the researcher had established unequivocally the correct diagnosis, mechanism of inheritance, and appropriate molecular test for the patient's condition.
Should this be considered research or clinical investigation?
Problems of research classification
Treating such cases as research creates important problems because of the process of ethical review. The first problem is that research ethics committees require consent to be closed-that is, samples must be used for a specific purpose and time which are clearly defined in advance. Small sample sizes in research into rare diseases mean that identifying disease-causing mutations is a type of informed fishing trip. The consent given is rarely capable of meeting the standards required.
Secondly, ethics committees do not always view the methods used to research rare conditions as meeting required methodological standards.
1 Lastly, research into rare conditions is criticised for its standards of confidentiality. Such research often involves studying unique or near unique cases, making it impossible for participants to be anonymous.
Defining this work as clinical investigation sidesteps these problems but creates a problematic regulatory loophole. We believe that researchers should accept the need for ethics review and encourage the development of a more sympathetic regulatory structure. Agreement is needed about when clinical investigation turns into research and what is appropriate ethical review of research into rare inherited disorders.
Research or clinical practice?
One argument for classifying the above case as a clinical investigation is that the aim of the investigation is not to generate knowledge for its own sake but to provide a diagnosis and information about inheritance risk. Secondly, although some have alleged that such activities differ from clinical practice because they involve family members, it is good clinical practice in genetics to involve family members whenever possible. Thirdly, as clinical practice, it would continue to be subject to appropriate levels of regulation. It would be subject to the law (for example, on negligence) and to professional guidance 2 and would not imply unacceptably low standards of protection.
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Although some aspects of the case resemble clinical practice, good reasons also exist for considering it as research. The characteristics that make such activities look insufficiently rigorous to ethic committees-that is, that they are fishing trips-also makes them look more like research than clinical practice. When a diagnosis is eventually reached, it is on the basis of a previously unknown mutation. It is not unusual for it take years to reach an understanding of the biological mechanisms, and the results are often published in peer reviewed journals. In addition, the involvement of family members can evolve into something that no one would dispute was research. The most obvious point at which this happens is when case finding moves from a single family to a search for additional affected individuals and families. Finally, classifying investigations as research may provide access to funding that would otherwise be unavailable.
When does clinical practice become research?
An unambiguous distinction between clinical practice and research is impossible. Some differences are discernable, however. Once an investigation moves from a single family to the solicitation of affected but unrelated individuals it has undeniably become research. At the other end of the spectrum, when mutations are searched for to find a diagnosis in an individual, this looks like clinical practice, as does checking against samples from blood relatives to see whether the patient has a de novo mutation.
Between these two markers things become less clear, and it is unrealistic to expect to find an unambiguous dividing line. Given this, a pragmatic solution is required. We suggest that investigations that go beyond the identification of mutations in unsolicited single families (and confirmation or exclusion in blood relatives) should be considered as research and subject to ethical review-in other words, studies in which the researcher actively recruits new cases.
Improving ethical review
Developing tests and therapies for rare genetic disorders depends on a more sympathetic approach to the review of such research. What should be the appropriate process of research ethics review? The best way to consider this is in terms of the three problems identified earlier: consent, anonymity, and methodology.
Open ended versus closed consent
Except in exceptional circumstances, research participants should be included in studies only if they have given their valid consent. What ought to count as valid consent in research into rare conditions?
To be valid, consent must be voluntary, informed, and competently given. Research ethic committees have tended to interpret the requirement for informed consent to imply that such consent must be specific and closed. Consent is informed only if participants know in detail what is going to happen to them, what is going to happen to any sample taken from them, and when the research will be completed. In research into rare conditions it is not always possible to provide the participant with a detailed account of this kind. This need not imply, however, that informed consent is not possible. Given adequate support, research participants are able to understand the nature of rare disease research sufficiently well to enable them to give valid consent. The true test of validity, we suggest, is whether the participants have sufficient understanding of the research and of their part in it to enable them to make a reasoned and balanced assessment about whether to participate.
Anonymity
High standards of confidentiality and anonymity are important in research. When asked, patients and research participants consistently place high value on confidentiality. They also place high value on good quality research and the achievement of results. 4 In rare disorders these goals need to be carefully balanced against the realities of such research. The appropriate balance between anonymity and research efficacy should be judged according to a combination of empirical evidence about what participants consider acceptable practice and recognition of the need to protect family members who do not want participate in research.
Rigorous methodology
It is unreasonable for ethics committees to apply inappropriate standards of research methodology to research on rare diseases. Research on small sample sizes requires different methods from those used in large trials. The review of research into rare inherited disorders should ensure that the research methods are appropriate to the task.
Conclusions
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